Live Price Coverage: Omeros Corporation Can’t Burn Your Short Portfolio. Has Another Weak Session

Live Price Coverage: Omeros Corporation Can't Burn Your Short Portfolio. Has Another Weak Session

The stock of Omeros Corporation (NASDAQ:OMER) is a huge mover today! The stock decreased 3.73% or $0.39 during the last trading session, hitting $10.07. About 434,397 shares traded hands or 65.44% up from the average. Omeros Corporation (NASDAQ:OMER) has declined 6.52% since March 2, 2016 and is downtrending. It has underperformed by 14.78% the S&P500.
The move comes after 9 months negative chart setup for the $413.55M company. It was reported on Oct, 6 by Barchart.com. We have $8.86 PT which if reached, will make NASDAQ:OMER worth $49.63 million less.

Analysts await Omeros Corporation (NASDAQ:OMER) to report earnings on November, 14. They expect $-0.30 EPS, up 34.78% or $0.16 from last year’s $-0.46 per share. After $-0.24 actual EPS reported by Omeros Corporation for the previous quarter, Wall Street now forecasts 25.00% negative EPS growth.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Out of 6 analysts covering Omeros (NASDAQ:OMER), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Omeros has been the topic of 10 analyst reports since August 10, 2015 according to StockzIntelligence Inc. WBB Securities maintained the shares of OMER in a report on Tuesday, August 18 with “Strong Buy” rating. TH Capital initiated Omeros Corporation (NASDAQ:OMER) on Monday, August 10 with “Buy” rating. The rating was maintained by Needham on Wednesday, November 11 with “Buy”. The stock of Omeros Corporation (NASDAQ:OMER) has “Buy” rating given on Friday, June 3 by Cantor Fitzgerald. As per Tuesday, August 18, the company rating was maintained by Cowen & Co. The company was maintained on Monday, August 31 by Needham. The firm earned “Buy” rating on Monday, August 10 by Roth Capital.

According to Zacks Investment Research, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.”

Insitutional Activity: The institutional sentiment decreased to 0.77 in Q2 2016. Its down 0.21, from 0.98 in 2016Q1. The ratio dived, as 15 funds sold all Omeros Corporation shares owned while 32 reduced positions. 13 funds bought stakes while 23 increased positions. They now own 19.91 million shares or 14.90% more from 17.33 million shares in 2016Q1.
Geode Mngmt Ltd Liability Com last reported 0% of its portfolio in the stock. Mackenzie Corp last reported 114,400 shares in the company. New York State Common Retirement Fund owns 114,695 shares or 0% of their US portfolio. Ladenburg Thalmann has 1,770 shares for 0% of their US portfolio. Architects Inc has 400 shares for 0% of their US portfolio. Blackrock Institutional Tru Na last reported 912,201 shares in the company. Alliancebernstein Lp has invested 0% of its portfolio in Omeros Corporation (NASDAQ:OMER). First Republic Invest Mgmt owns 53,000 shares or 0.01% of their US portfolio. Bnp Paribas Arbitrage holds 0% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 1,440 shares. Moreover, Brown Advisory Incorporated has 0.02% invested in Omeros Corporation (NASDAQ:OMER) for 543,763 shares. Tocqueville Asset Management L P accumulated 0.13% or 956,003 shares. Mutual Of America Cap Management holds 115,371 shares or 0.03% of its portfolio. Lpl Financial Ltd Liability accumulated 10,120 shares or 0% of the stock. Lesa Sroufe accumulated 0.25% or 26,890 shares. California Pub Employees Retirement Sys owns 60,800 shares or 0% of their US portfolio.

Insider Transactions: Since April 15, 2016, the stock had 0 insider buys, and 6 selling transactions for $973,913 net activity. $158,057 worth of shares were sold by Kelbon Marcia S. on Monday, May 16. 3,000 Omeros Corporation (NASDAQ:OMER) shares with value of $34,557 were sold by Cable Thomas J..

More notable recent Omeros Corporation (NASDAQ:OMER) news were published by: Fool.com which released: “Why Omeros Corporation’s Stock Dropped Today” on August 11, 2016, also Prnewswire.com with their article: “Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European …” published on July 28, 2016, Fool.com published: “Is This The Reason That Omeros Corporation Fell 17.7% in April?” on May 06, 2016. More interesting news about Omeros Corporation (NASDAQ:OMER) were released by: Fool.com and their article: “Why Omeros Corporation Dropped 12% in February” published on March 08, 2016 as well as Businesswire.com‘s news article titled: “Omeros Corporation Reports Second Quarter 2016 Financial Results” with publication date: August 09, 2016.

OMER Company Profile

Omeros Corporation, incorporated on June 16, 1994, is a biopharmaceutical company. The Firm is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is launched in the United States for use during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from the Company’s PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. The Company’s PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment